VELCADE,Rituximab,Cyclophosphamide and Decadron

• Status: Terminated
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oncology Specialists, S.C.
• Collaborator: Millennium Pharmaceuticals, Inc.
• Treatments: BB 1101; Bortezomib; Cyclophosphamide; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Rituximab

Criteria

Inclusion Criteria:

• Small Lymphocytic Lymphoma

• Follicular Cell Lymphoma (grades I and II)

• Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy and stem cell transplant

• Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia

• Marginal Zone Lymphoma

• MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation.

• Adequate bone marrow function, renal function, and hepatic function as outlined in details below.

• ECOG performance status of 0, 1, or 2

• Able to read, understand, and sign an IRB approved informed consent

Exclusion Criteria:

• Known HIV positive status

• Known CNS involvement

• Prior therapy for lymphoma EXCLUDING antibiotic treatment for MALT-Type NHL.